WOODBRIDGE, ON, Sept. 4, 2012 /CNW/ - Pivotal Therapeutics Inc. (OTCQX: PVTTF) (CNSX: PVO), a specialty pharmaceutical company with a focus on cardiovascular
disease and overall health, is pleased to announce that the company
received a positive response to its lead product VASCAZEN™ at the European Society of Cardiology (ESC) Congress 2012 in Munich,
Germany last week. The ESC Congress provided the Company a platform to
inform healthcare professionals from around the world on the benefits
of VASCAZEN™ and its unique approach to Omega-3 therapy.
The expanded scientific study presented at the ESC Congress that
demonstrated the superiority of VASCAZEN™'s formulation was well received by the large audience of delegates
interested in Omega-3 and cardiovascular health. The study, entitled The highly purified EPA:DHA 6:1 product evokes potent
endothelium-dependent relaxations of porcine coronary artery rings via
the redox-sensitive PI3-kinase/Akt-dependent phosphorylation of eNOS, was authored by F. Zgheel, M. Alhosin, C. Auger and V.B. Schini-Kerth
and conducted at the University of Strasbourg, Illkirch, France.
"Scientific findings on VASCAZEN™'s cellular and membrane effects, in addition to its superior
vasodilatory profile, was presented and appreciated by a large audience
of clinicians and scientists that attended the oral presentation given
at the ESC Congress" said Dr. George Jackowski, Chairman and Chief
Scientific Officer. "This conference was attended by over 26,000
individuals working in the cardiovascular field from all over the
world, and the data collected on our unique formulation demonstrated to
this audience that not all Omega-3 formulations are the same and showed
VASCAZEN™'s superiority over other prescription only products."
About Pivotal Therapeutics Inc.
With offices in Toronto, Canada and Boca Raton, Florida, Pivotal
Therapeutics is a publicly traded (OTCQX: PVTTF); (CNSX: PVO) specialty
pharmaceutical company with a focus on cardiovascular disease and
overall health. Pivotal Therapeutics' lead product VASCAZEN™ is a prescription only Medical Food formulated to meet the dietary
Omega-3 deficient needs of patients with cardiovascular disease through
elevating Eicosapentaenoic acid (EPA) and Docosahexaenoic acid (DHA) to
levels associated with reduced risk of cardiovascular complications.
VASCAZEN™ is a >90% pure, proprietary EPA:DHA fatty acid formulation, protected
by a series of both issued and pending US and foreign patents and
commercialized as a prescription only Medical Food in the U.S. This
unique formulation will provide the cornerstone upon which a family of
cutting edge combination products, with efficacy across a broad
spectrum of cardiac care, will be commercialized.
OMAZEN™ is a >90% pure, proprietary EPA:DHA fatty acid formulation
commercialized for sale and distribution in Canada for the maintenance
of good health through elevating Omega-3 fatty acid levels. The unique
formulation and dosage will be available to patients and consumers who
realize the health benefits of Omega-3 supplementation with a quality
The information contained in this document is as of September 4, 2012.
This press release contains forward-looking statements. Such
forward-looking statements are subject to a number of risks,
assumptions and uncertainties that could cause Pivotal's actual results
to differ materially from those projected in such forward-looking
statements. These statements can be identified by the use of words such
as "will", "anticipate", "estimate", "expect", "project", "forecast",
"intend", "plan", "believe", "project", "potential", and similar
expressions with any discussion of future operating or financial
performance or events. In particular, factors that could cause actual
results to differ materially from those in forward looking statements
include the following: Pivotal's inability to obtain additional
financing on acceptable terms; growth in costs and expenses; inability
to compete with others who provide comparable products; risk that the
Company's products will not gain widespread market acceptance; risks
relating to the Company's ability to maintain its CSNX listing.
Forward-looking statements speak only as of the date made and are not
guarantees of future performance. The Company undertakes no obligation
to publicly update or revise any forward-looking statements contained
in this document as a result of new information or future events or
developments. CNSX has not reviewed and does not accept responsibility
for the adequacy or accuracy of this information.
SOURCE: Pivotal Therapeutics Inc.
For further information:
President and Chief Operating Officer
Communications and Public Relations Manager
Phone: 905-856-9797 ext. 231
Pivotal Therapeutics Inc.